å»è¬åå ¬è¡šãããæŽå¯
Osteoarthritisã¯ãŸãåçã®é¢ç¯çãšããŠç¥ãããŠããããç¹ã«èãéŠããã³ããäœãèéšã®ãããã«åœ±é¿ãäžããæãäžè¬ã«èµ·ãããŸããæ ¢æ§ç¶æ ã§ãã Osteoarthritisã¯åœ±é¿ãããããã£éšåã®éåºŠã®æ¥åç®æã®èŠçãããŠåãã«å°ããŸãã ãããã®çç¶ã¯ãããã€ãã®ç©ççãªéåã®åŸã«åææ®µéã§èµ·ããããšããããŸãããæŽ»åã®åŸã®é·ãæç¶ããŸãã 骚é¢ç¯çã®ä»ã®ããã€ãã®çç¶ã«ã¯ãéåã®æžå°ç¯å²ãé¢ç¯ã®è «ããè¶³ãè ã®ãã³ããªã©ããããŸãã æã®ç«¯éšãéŠãè °éšãèã®åºéšã«ã¯ãæã®ç«¯éšãã»ãšãã©èŠãããŸãã 骚é¢ç¯çã®é²è¡ã¯åããã¿ãŒã³ã§çµæããããããæçµçã«é¢ç¯ã®èåãéåžžã¯èã§çµæã... ãã£ãšèŠã
æèªæ®ºè¬ - Horizonã§ã®ç掻ã®Beaconã©ã€ããã€ç ã¯ãäžçäžã®äž»èŠãªãã«ã¹ã±ã¢ã®è² æ ã®1ã€ã§ããçç£æ§ãäœäžãããæ·±å»ãªã±ãŒã¹ã§ã¯ãèªæ®ºåŸåã«ã€ãªããã æãã€è¬ãšæç²Ÿç¥è¬ã¯ãç¹ã«çµæžå±æ©ãšç€ŸäŒçé倱ã®éã®éèŠãé«ãã§ãã ãããã®è¬ã¯ãèªæ®ºã®æèã詊ã¿ãé²ãããã®æ²»çãšããŠåœ¹ç«ã¡ãŸãã ãããããããã®è¬ã®éå°æåã¯èŽåœçã§ããããããã£ãŠãå»åž«ã®æç€ºã®äžã§æäžããå¿ èŠããããŸãã èªæ®ºæ²»çã«é¢ããåºç¯ãªç ç©¶ã¯ãäºæž¬æéã®åŸåã«äžçã®äººå£ã«ããè¯ããœãªã¥ãŒã·ã§ã³ãæäŸããããšãæåŸ ãããŸã(2019-2027)ã ããã¯ãäžççãªæèªæ®ºè¬åžå Žã®èŠéããæ¹åããèªæ®ºã«ããæ»ãæžãã... ãã£ãšèŠã
3Dããªã³ãå»è¬ååžå Žããã¯ãããžãŒå¥ïŒç±æº¶èå ç©ã¢ããªã³ã°ïŒFDMïŒãå é 圢ïŒSLAïŒãã€ã³ã¯ãžã§ããå°å·ãããã³éžæçã¬ãŒã¶ãŒçŒçµïŒSLSïŒïŒãã¢ããªã±ãŒã·ã§ã³å¥ïŒåå¥åå»çãè¬ç©ééã·ã¹ãã ãçµç¹å·¥åŠãèšåºç ç©¶ããã³æ²»éšïŒããšã³ããŠãŒã¶ãŒå¥ïŒè£œè¬äŒç€Ÿããã€ãªãã¯ãããžãŒäŒæ¥ãåèšç ç©¶æ©é¢ïŒCROïŒãåŠè¡ç ç©¶æ©é¢ãç é¢ããã³ ã¯ãªããã¯ïŒãè¬å€ã¿ã€ãå¥ïŒäœååå»è¬åããã³çç©è£œå€ïŒã補å圢æ å¥ïŒé å€ãã«ãã»ã«ã泚å°å€ãããã³ãã®ä»ã®åœ¢æ ïŒãææã¿ã€ãå¥ïŒããªããŒãçåè§£æ§ææããããã²ã«ãããã³éå±ïŒãæµéãã£ãã«å¥ïŒãªã³ã©ã€ã³ããã³ãªãã©ã€ã³ïŒãå°çå¥ïŒåç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©... ãã£ãšèŠã
ãªã³ãè «ã¯ããªã³ãçãšããŠç¥ãããŠããå ç«ã·ã¹ãã ã®çްèã«åœ±é¿ãåãŒããªã³ãç³»ã®çãæãã现èã®ç°åžžãªå¢æ®ããã³å¢æ®ããããããŸãã ãªã³ãçã¯ãææããäœãä¿è·ããçœè¡çã§ãã ããã¯2ã€ã®ã¿ã€ããããªãã¡ãéãããã³ããã³ãããã³ã®ãªã³ãè «ã§ãã æ¿Ÿèæ§ãªã³ãè «ã¯ããªã³ãçã«åœ±é¿ãäžããéããžãã³ãªã³ãè «ã®äžçš®ã§ãã éããžãã³ãªã³ãè «ã®æãäžè¬çãªå¶æ°åã§ãã æ¿Ÿèæ§ãªã³ãè «ã¯ãéŠãéŒ åŸéšãè ¹éšã®ãªã³ãç¯ã®æ¡å€§ãåŒåžã®äžè¶³ãäœéæžå°ãå€éã®æ±ãç²åŽãªã©ã®çç¶ããããŸããæ¿Ÿèæ§ãªã³ãè «ã¯ãé¢é£ããçç¶ã®æ¥æ§ããã³çæé·çã«åºã¥ããŠæ²»çããããšãã§ããŸãã æŸå°ç·ãšååŠçæ³ã¯ãæ¿Ÿèæ§ãªã³ãè «... ãã£ãšèŠã
ã¢ã³ããšã€ãå»è¬å åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033ã°ããŒãã«åæ¥µè¬ åžå ŽèŠæš¡ã¯ã2026幎ã«12.7åç±³ãã«ã§è©äŸ¡ããã2033幎ãŸã§ã«19.3åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«antacidã®è¬ç©ã®åžå Žã¯å¿çŒããæ¶åäžè¯ããã³é žã®éæµãç·©åããããã«èé žãäžåãããããã¯ãã«çŠç¹ãåãããŸãã æé·ã¯ãèè žé害ãçæŽ»ç¿æ £é¢é£æ¶ååšã®åé¡ã®äžæã®åªå é äœã«ãã£ãŠé§åãããã»ã«ãã±ã¢ã®æ²»çã®æ¶è²»è æèãé«ããŸãã ã¢ã³ããšã€ãã¯ãã¿ãã¬ãããã±ãŒãã«ãæ¶²äœãããã³çºæ³¡äœã§å©çšå¯èœã§ãã åžå Žã¯ãåžè²©ã®å¯çšæ§ãèå人å£ãããã³äœ¿ãæšãŠã®åå ¥ã®å¢å ããæ©æµãåããŸãã äž»èŠãªãã¬... ãã£ãšèŠã
åç©ã®æé¬±è¬åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033äžççãªåç©ã®ãã€ç ã®è¬ã®åžå ŽèŠæš¡ã¯2026幎ã«1.2åç±³ãã«ã§è©äŸ¡ããã2033幎ãŸã§ã®10.5%ã®æ··åç©ã®å¹Žéæé·ç(CAGR)ã2026幎ãã2033幎ãŸã§æºãããšäºæ³ãããŸãã ãã®å ç¢ãªåžå Žæé·ã¯ã广çãªè¬ççä»å ¥ãšäž»èŠãªåžå Žå šäœã®èŠå¶åå®¹ãæ¡å€§ããããã®å¢å ã®éèŠãåæ ããŠããŸãããããã£ãŒã«åç©ã®ãã€ç ã®è¬ã®åžå Žã¯ãããããã³å®¶çã®ãã€ç ãäžå®ããã³é¢é£ã®è¡åé害ã管çããããã«èšèšãããŠããè¬åŠã®åŠçœ®ã«çŠç¹ãåãããŸãã ãããã®è¬ã¯ãæãã€è¬ãäžå®è¬ãããã³åç©ã®ããã«ç¹å¥ã«åŠæ¹ãããä»ã®ç²Ÿç¥ããããã¯è¬ãå«ãããã°ãã°... ãã£ãšèŠã
Von Willebrandç æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2026 - 2033ã°ããŒãã«Von Willebrandç æ²»çåžå ŽèŠæš¡ã¯ã2026幎ãã2033幎ãŸã§ã®8.9%ã®ååç©å¹Žéæé·ç(CAGR)ãæç€ºããUSD 3.25åç±³ãã«ã«éãããšäºæ³ãããŸãããããã£ãŒã«äžççãªVon Willebrandã®ç æ°(VWD)ã®åŠçœ®ã®åžå Žã¯å¢å ã®ç æ°ã®èªèãæ¹åããã蚺æããã³é²æ©ã«ãã£ãŠé転ãããéèŠãªæé·ãç®æããŠããŸã æ²»çè¬ ãªãã·ã§ã³ã æ²»çã«ã¯ããã¢ãã¬ã·ã³ããã©ãºãç±æ¥ããã³çµæãã®ãã©ã³ã»ãŠã£ã¬ãã©ã³ãå å補åãåºè¡ã®ãšããœãŒãã®äºé²ãšç®¡çãã¿ãŒã²ãã£ã³ã°ãå«ãŸããŸãã åç±³ã¯ãå é²... ãã£ãšèŠã
ã·ã³ã°ã«ã¹ã¯ã¯ãã³åžå ŽèŠæš¡ãšäºæž¬ - 2026 - 2033ã°ããŒãã«ã»ã·ã³ã°ã«ã»ã¯ã¯ãã³åžå ŽèŠæš¡ã¯ã2026幎ãã2033幎ãŸã§ã®USD 5.8åã§è©äŸ¡ããããšæšå®ãããUSD 11.6åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«äžççãªã·ã£ã€ã³ãžã«ã¯ã¯ãã³åžå Žã¯ãã·ã£ã€ã³ãžã«ãšãã®å䜵çã®æèãé«ããããšã«ãã£ãŠãç¹ã«èå人å£ã®äžã§åŒ·ãæé·ãç®æããŠããŸãã ã¯ã¯ãã³ã®ãããª çµæãã®zosterã¯ã¯ãã³ é«ãå¹åããã³å®å šãããã£ãŒã«ã«ãã鲿©ãåŸãŠããŸãã ãã«ã¹ã±ã¢ã®æ¯åºã®äžæ, æ¿åºã®å ç«ããã°ã©ã , å ç«å䜵çã®å人ã®å¢å ã®ãããªãçæåžå Žã®æ¡å€§. åã¢ã¡ãªã«ã¯åžå Žãæ¯é ããŸããã¢... ãã£ãšèŠã
äœå® ã®ç¥çè²¡ç£ åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033ã°ããŒãã«ã»ã¬ãžãã³ã·ã£ã«ã»ç¥è²¡éããæœèš åžå ŽèŠæš¡ã¯ã2026幎ã«18.3åç±³ãã«ã§è©äŸ¡ããã2033幎ãŸã§ã®USD 29.1åç±³ãã«ã«éãããšäºæ³ããã2026幎ãã2033幎ãŸã§ã®6.2%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«ãã®åžå Žã¯ãé·æçãªäœå® ã®äžè©±ããµããŒããµãŒãã¹ããããŠãç¥çããã³çºéé害ãæã€å人ã®ããã®ç掻ç°å¢ãæäŸããããšã«çŠç¹ãåœãŠãŠããŸãã ãã®åžå Žã«ã¯ãã°ã«ãŒãããŒã ããµããŒããããå± äœæœèšãããã³å°éã®äœå® ä»è·æœèšãå«ãŸããŠãããããŒãœãã«ã±ã¢ãè¡åæ¯æŽãã©ã€ãã¹ãã«ãã¬ãŒãã³ã°ã... ãã£ãšèŠã
èç«ã°ã©ãŠã³ãæ²»çåžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033äžççãªèç«æ§ã°ã©ãŠã³ãæ²»çåžå ŽèŠæš¡ã¯ã2026幎ã«1.4åç±³ãã«ã§è©äŸ¡ããã2033幎ãŸã§ã®7.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããUSD 2.3åç±³ãã«ã«éãããšäºæ³ãããŸãããããã£ãŒã«èç«æ§ã°ã©ãŠã³ãæ²»çåžå Žã¯ãæ²»çã«éç¹ã眮ããŠããŸã ã°ã©ãŠã³ã³ã« æå€§ã®å»çãå€ç§çä»å ¥ã«ãããããããå¶åŸ¡ãããŠããªãã±ãŒã¹ã èç«æ§ã°ã©ãŠã³ãã¯ããã°ãã°çŒå§ã®æç¶çãªäžæãšèŠåã®æå€±ã®ãªã¹ã¯ãé«ããããé«åºŠãªæ²»çã¢ãããŒããå¿ èŠãšããŸãã åžå Žã¯ãå»è¬åçæ³ãã°ã«ã³ãææ°Žè£ 眮ãæå°äŸµè¥²çã°ã«ã³ãæè¡(MIGS)ãã¬ãŒã¶ãŒæ²»çããã... ãã£ãšèŠã
Proteinuriaã¯å°¿äžã®ã¿ã³ãã¯è³ªã¬ãã«ã®å¢å ãšããŠå®çŸ©ãããŠããŸãã ã¿ã³ãã¯è³ªå°¿çŽ ã®ç¶æ ã¯ããã°ãã°è èç ã®åŸŽåã§ãã ããããŒã¯ãã¡ã€ã³æ©èœãè¡æ¶²ã濟éããè±åœ¢ã®èåšã§ãã è èã¯ãè¡ããã®å°¿ããã³åžåæ§ã¿ã³ãã¯è³ªãã廿£ç©ãé€å»ããã°ã«ããŒãªãšåŒã°ããè¡ç®¡ãå«ãŸããŠããŸãã ããããè èãã°ãªããŒãªãæå·ãåããå Žåãã¢ã«ãã³ãªã©ã®ã¿ã³ãã¯è³ªã¯ã誀ã£ãŠå°¿ã«å ¥ãããšããããŸãã ããããã«ãããã¯ã¿ã³ãã¯è³ªå°¿äžã®é«ã¿ã³ãã¯è³ªã¬ãã«ã«ã€ãªãããŸãã è èæ©èœã®é²æ©çãªäœäžã¯ãæçµçã«éæãŸãã¯è èç§»æ€ãå¿ èŠãšããå¯èœæ§ããããŸãã ç³å°¿ç ããã³é«ãè¡å§ã¯ãäž¡æ¹è èã«å®³ãåãŒãããšãã§... ãã£ãšèŠã
ã©ã€ãã¹ã¿ã€ã«è¬ã¯ãçæŽ»ç¿æ £ç ã®æ²»çã«äœ¿çšãããè¬ã§ãã ãããã¯ããã«ãã£ãã¹ãã€ã³ããã³ã¹ããããã¢ã«ã³ãŒã«äŸåçãŸãã¯å«ç ãå«ããç§ãã¡ã®ã©ã€ãã¹ã¿ã€ã«ã®éžæããäžæããç æ°ã§ãã ãããã®æ¡ä»¶ã¯ãã»ãšãã©éè è¿«ãšéçã¿ã§ãã åžè²©ã®ã©ã€ãã¹ã¿ã€ã«è¬ã¯ã1ã€ã®å€èгã ãã§ãªãã身äœçããã³ç²Ÿç¥çãªèœåãå€ããããã«äœ¿çšããããšãã§ããŸããã©ã€ãã¹ã¿ã€ã«è¬ã®ããã€ãã®äŸã«ã¯ãViagra(ã·ã«ãããã£ã«ã¯ãšã³é žå¡©)ãå«ãŸããŠããŸãã åèµ·äžå šãLatisse ããã³ Botox ã¯ãšãã«ã®ãŒããã³çŠç¹ãé«ããããã«äœ¿çšãããåç²§åé¢é£ã®è¬å€ãProvigil (modafinil)ãšããŠäœ¿çš... ãã£ãšèŠã
Behcetã®çå矀ã¯ãããŒã¿ç (BD)ãšãåŒã°ããäœã®å ç«ç³»ãç¬èªã®å¥åº·ãªçްèã®äžéšãç Žå£ããèªå·±å ç«é害ã§ãã ããã¯äœã®ããã€ãã®é åã«åœ±é¿ãäžããããšãã§ããççæ§ããã³éäŒææ§çŸæ£ã§ãã ãã®ç¶æ ã®åå ã¯äžæã§ãããèªç¶ã®äžã§éºäŒçãšèããããŠããŸãã Behcet ã®çå矀ã¯ãå°ãªããšã 1 幎ã«ããŠã¹ã®çã¿ã® 3 ã€ã®ã€ã³ã¹ã¿ã³ã¹ãããå Žåãå°ãªããšã 2 ã€ã®çæ®åšã®çã¿ãç®ã®åºæ¿ãç®èã®çã¿ããã©ã¹ã®ç®èã® prick ãã¹ãã蚺æãããŸãã ãããçå矀ã®çç¶ã¯äººãã人ãŸã§ç°ãªããŸãã ãã®çç¶ã¯ãè¡ç®¡ã®ççã«ãã£ãŠåŒãèµ·ããããããšãç¥ãããŠããŸã(è¡ç®¡ç)ã ç æ°ã¯ãã... ãã£ãšèŠã
èºæµ®è «ã¯èºã®æµäœã®èç©ã«ãã£ãŠåŒãèµ·ããããç¶æ ã§ãã ãã®æµäœã¯èºã®å€æ°ã®ç©ºæ°ã®å¢ã«èç©ããåŒåžå°é£ã«ããŸãã èºæµ®è «ã¯ãäœå ã®æ°Žåã®èç©ãå§ãŸã2çš®é¡ã«åé¡ãããŸãã å¿èé害ãªã©ã®å¿èã®åé¡ã«ãã£ãŠåŒãèµ·ãããããšãå¿èã®èºæµ®è «ãèµ·ãããŸãã å¿èé害ã¯éåžžãèºã®æµ®è «ãåŒãèµ·ãããŸãã éå¿èç æ§èºæµ®è «ã¯ãæ¥æ§åŒåžåšçŸæ£çå矀(ARDS)ãé«åºŠèºæµ®è «(HAPE)ãªã©ã®éå¿çŸæ£ã«ãã£ãŠåŒãèµ·ããããã èºæµ®è «ã¯ãå¿ãšå¿ä»¥å€ã®æ¡ä»¶ã®äž¡æ¹ã«ãã£ãŠåŒãèµ·ããããããšããããŸããæ¥æ§ã®èºæµ®è «ã®ããã®åŠçœ®ã®æåã®ã©ã€ã³ã¯è£è¶³ã®é žçŽ ãå«ãã§ããŸããããã¯éåžžãéããŠç®¡çãããŸã ããµã«ã«ã³ãã©ãåno... ãã£ãšèŠã
æ¿ããæ¥æ§åŒåžçå矀(SARS)ã¯ãèŽåœçãã€äŒææ§ã§ããããšãã§ãããŠã€ã«ã¹æ§åŒåžåšçŸæ£ã§ãã SARSãšCOVID-19ã®äž¡æ¹ããSARSãèªããã³ãããŠã€ã«ã¹ã«ãã£ãŠåŒãèµ·ããããŸãã ãŠã€ã«ã¹SARS-CoVããã³COVID-19ã«ããSARSã¯ãŠã€ã«ã¹SARS-CoV2ã«ãã£ãŠåŒãèµ·ããããŸãã ææSARS-CoVããã³COVID-19ã¯åç©ãšäººéã®äž¡æ¹ã§èµ·ãããŸããç æ°ã®ã³ã³ãããŒã«ãšäºé²(CDC)ãšäžçä¿å¥æ©é¢(WHO)ã®ã»ã³ã¿ãŒã«ãããšãSARSã¯2002幎11æä»¥éã«åäžåœã§æ€åºããã2003幎3æä»¥éã«SARSã¯ã°ããŒãã«ãã¶ãŒããšããŠèå¥ãããŸããã çŸç äºé²ã»ã³ã¿ãŒ(... ãã£ãšèŠã
ç¥çµå åæ³ããæ²»çåžå Žãè¬å€ã¯ã©ã¹å¥ïŒãœããã¹ã¿ãã³é¡äŒŒäœãååŠçæ³å€ãæšççæ³è¬ãå ç«èª¿ç¯è¬ãããããåå®¹äœæŸå°æ§æ žçš®çæ³ïŒPRRTïŒããã«ã¢ã³å€ïŒãé©å¿çã¿ã€ãå¥ïŒèè žèµç¥çµå åæ³è «çïŒGEP-NETïŒãèºç¥çµå åæ³ïŒ è «çãç²ç¶è ºç¥çµå åæ³è «çããã®ä»ïŒå¯è ç¥çµå åæ³è «çãªã©ïŒïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ãããæ²»çã»ã³ã¿ãŒã倿¥æè¡ã»ã³ã¿ãŒãåšå® å»çãç ç©¶æ©é¢ïŒãæäžçµè·¯å¥ïŒçµå£ããã³éçµå£ïŒãæµéãã£ãã«å¥ïŒç é¢ã®è¬å±ãå°å£²è¬å±ããªã³ã©ã€ã³è¬å±ïŒãå°çå¥ïŒåç±³ã ã©ãã³ã¢ã¡ãªã«ããšãŒããããã¢ãžã¢å€ªå¹³æŽãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
å»è¬åã¯ãäž»ã«å®éšå®€ã§è£œé ãããèšèšãéçºã補é ãããŠããŸãã å®éšå®€ã®è¬å€ã®ãã¹ãã¯åæã®ãã¹ãããå質管ç(QC)ããã³ããã»ã¹ææåã³å®æåã®é©é圢æ ãžã®è¬å€ã®ç ç©¶éçºãããŠçç£ã®ã»ãšãã©ãã¹ãŠã®æ®µéã§èŠæ±ãããŸããå»è¬åæ€æ»ã¯ãå¹åãå¹åãããã³é©åãªäœ¿çšãŸãã¯å»ç補åã®æäžéãæ±ºå®ããã ãã§ãªãããã®ç²ŸåºŠãšå®å®æ§ã枬å®ããŸãã å»è¬åæ€æ»å®€ã¯ã補åãæ€æ»ãã補åã販売ããåã«ã誰ããå®å šã«äœ¿çšã§ããããã«æ¯æŽããŸããæ¹æ³éçº, å è£ ææ ãã¹ããããã»ã¹éçºããã³è§£æŸã®ãã¹ãã¯è¬å€ã®ãã¹ãã®å®éšå®€ãè¬ã®å®å šãä¿éããããã«æäŸããããŸããŸãªãµãŒãã¹ã®å°æ°ã§ããã°ããŒãã«å»è¬åæ€æ»ãµãŒ... ãã£ãšèŠã
ããã·ãªã³ã³ãã©ãã°ããªããªãŒãã©ãããã©ãŒã åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033ã°ããŒãã«ããã·ãªã³ã³å»è¬åé ä¿¡ãã©ãããã©ãŒã åžå ŽèŠæš¡ã¯ãããŸã 2026幎ã®USD 2.6åã§è©äŸ¡ããããšäºæ³ããã 2033幎ãŸã§ã«USD 6.4åã«éããååç©ã®å¹Žéæé·çã瀺ã 2026幎ãã2033幎ã«ãããŠ12.4%ã®CAGRããããã£ãŒã«ãããããã ã·ãªã³ã³ å»è¬å ããªããªãŒ ãã©ãããã©ãŒã ã¯å€å質ãŸãã¯æ§é ã®ã±ã€çŽ ãå©çšããŸã ããç²åã¯ãå¶åŸ¡ãããæ²»çè¬ãéã¶ãšè§£æŸããŸã ãåãåãã ãããã®ãã©ãããã©ãŒã ã¯ãè¬ç©ã®å®å®æ§ãåäžãããããã«èšèšããã ç¹å®ã®çµç¹ã现èãžã®ãã€... ãã£ãšèŠã